Table 11.

Efficacy of 90 mg ledipasvir + 400 mg sofosbuvir, QD for 12 weeks.

Cirrhosis	Prior treatment	SVR12 rate					Study and trial phase	Ref.
		GT-1	GT-3	GT-4	GT-5	GT-6
No cirrhosis	Naïve	94.7% (18/19)					LONESTAR, phase 2	Lawitz et al., 2014b
	Experienced	100% (8/8)
	Naïve	1a:100% (11/11), 1b:100% (9/9)					Phase 2a	Kohli et al., 2015a
	Naïve or experienced			92.9% (13/14)			NIAID, phase 2a	Kohli et al., 2015b
	Naïve or experienced		76.2% (16/21)			95.7% (22/23)	ELECTRON-2, phase 2	Gane et al., 2015
	Experienced	100% (7/7)					SPARE, phase 2a	Osinusi et al., 2014
	Experienced	91.2% (31/34)					NIAID synergy, phase 2a	Wilson et al., 2016
	Naïve			95.2% (20/21)			Phase 2	Abergel et al., 2016a
	Experienced			84.6% (11/13)
	Naïve				94.4% (17/18)		Phase 2	(Abergel et al., 2016b)
	Experienced				100% (14/14)
	Naïve	100% (70/70)					GS-US-337-0113, phase 3	Mizokami et al., 2015
	Experienced	100% (60/60)
	Naïve	100% (179/179)					ION-1, phase 3	Afdhal et al., 2014a
	Experienced	96.2% (50/52)					ION-2, phase 3	Afdhal et al., 2014b
	Experienced	94.3% (33/35)
	Naïve	1a: 94.8% (163/172), 1b: 97.7% (43/44)					ION-3, phase 3	Kowdley et al., 2014a
	Naïve	1a: 94.6% (406/429), 1b: 98.3% (172/175)					TRIO, real-world study	Younossi et al., 2016
	Naïve	1a:95.7% (1352/1413), 1b:95.2% (415/436)					Real-world study	Ioannou et al., 2016
	Experienced	1a:96.7% (472/488), 1b:95.6% (175/183)
Cirrhosis	Experienced	90.9% (10/11)					LONESTAR, phase 2	Lawitz et al., 2014b
	Naïve			100% (1/1)			Phase 2	Abergel et al., 2016a
	Experienced			100% (9/9)
	Naïve				100% (3/3)		Phase 2	Abergel et al., 2016b
	Experienced				83.3% (5/6)
	Null response	70% (7/10)					Phase 2	Gane et al., 2014a
	Naïve or experienced			100% (7/7)			NIAID, phase 2a	Kohli et al., 2015b
	Experienced	70% (7/10)					ELECTRON-1, phase 2	Gane et al., 2013b
	Naïve or experienced		25% (1/4)			100% (2/2)	ELECTRON-2, phase 2	Gane et al., 2015
	Naïve	96.9% (32/33)					ION-1, phase 3	Afdhal et al., 2014a
	PI + PegIFNα+RBV	85.7% (12/14)					ION-2, phase 3	Afdhal et al., 2014b
	PegIFNα+RBV	87.5% (7/8)
	Naïve	100% (13/13)					GS-US-337-0113, phase 3	Mizokami et al., 2015
	Experienced	100% (28/28)
	Naïve	1a:91.7% (483/527), 1b:93.6% (162/173)					Real-world study	Ioannou et al., 2016
	Experienced	1a:90.7% (68/75), 1b:100% (38/38)
	Experienced	76.9% (10/13) a	40% (2/5)a				Real-world study	Cheung et al., 2016

^aSVR24 rates were evaluated in the clinical study.